Daron Evans - 24 May 2021 Form 4/A - Amendment Insider Report for NEPHROS INC (NEPH)

Reporting relationship: CEO Specialty Renal Products
Issuer ticker: NEPH
Reported as of: 24 May 2021
Net transaction value: -$1,885
SEC form: 4/A - Amendment
Accepted by SEC: 01 Jun 2021, 17:39:58 UTC
Original report date: 25 May 2021
Next SEC filing: 25 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Daron Evans

Key filing fact

Daron Evans filed Form 4/A - Amendment for NEPHROS INC (NEPH) on 01 Jun 2021.

Key facts

This page summarizes Daron Evans's Form 4/A - Amendment filing for NEPHROS INC (NEPH).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 01 Jun 2021, 17:39.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: -$1,885.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NEPH transaction

Common Stock

Tax liability

Transaction value: $942
Shares: -349
Change %: -3.8%
Price: $2.70
Shares after: 8,947
Date: 27 May 2021
Ownership: By UTMA #1

NEPH transaction

Common Stock

Tax liability

Transaction value: $942
Shares: -349
Change %: -3.9%
Price: $2.70
Shares after: 8,669
Date: 27 May 2021
Ownership: By UTMA #2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

This amendment is being filed solely to report the unintentional omission of the withholding of shares otherwise to be issued to each of UTMA #1 and UTMA #2 in connection with the previously reported cashless warrant exercises.